This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Gamma-amino-beta-hydroxybutyric acid is an anticonvulsant indicated to treat convulsions in children and epilepsy.
- Generic Name
- Gamma-amino-beta-hydroxybutyric acid
- DrugBank Accession Number
- DB15985
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Gamma-amino-beta-hydroxybutyric acid (DB15985)
- Weight
- Average: 119.12
Monoisotopic: 119.058243154 - Chemical Formula
- C4H9NO3
- Synonyms
- 4-Amino-3-hydroxybutyric acid
- Buxamine
- Gamma-amino-beta-hydroxybutyric acid
- External IDs
- 213-106-9
- NSC-40244
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used as adjunct in combination to treat Behavioural disorders Combination Product in combination with: Diazepam (DB00829) •••••••••••• •••••• Used as adjunct in combination to treat Convulsion in childhood Combination Product in combination with: Diazepam (DB00829) •••••••••••• •••••• Treatment of Idiopathic epilepsy •••••••••••• •••••• Used as adjunct in combination to treat Partial-onset seizures Combination Product in combination with: Diazepam (DB00829) •••••••••••• •••••• Treatment of Symptomatic epilepsy •••••••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 1ZHM019FLD
- CAS number
- 924-49-2
- InChI Key
- YQGDEPYYFWUPGO-UHFFFAOYSA-N
- InChI
- InChI=1S/C4H9NO3/c5-2-3(6)1-4(7)8/h3,6H,1-2,5H2,(H,7,8)
- IUPAC Name
- 4-amino-3-hydroxybutanoic acid
- SMILES
- NCC(O)CC(O)=O
References
- General References
- AIFA: Gamibetal (Gamma-amino-beta-hydroxybutyric Acid) Oral Tablet [Link]
- External Links
- Human Metabolome Database
- HMDB0061877
- KEGG Compound
- C03678
- ChemSpider
- 2064
- ChEBI
- 16080
- ChEMBL
- CHEMBL93515
- Wikipedia
- Gamma-Amino-beta-hydroxybutyric_acid
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 453.0 mg/mL ALOGPS logP -3.4 ALOGPS logP -3.8 Chemaxon logS 0.58 ALOGPS pKa (Strongest Acidic) 4.1 Chemaxon pKa (Strongest Basic) 9.6 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 83.55 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 26.67 m3·mol-1 Chemaxon Polarizability 11.35 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-00di-9300000000-8580fd9fa08f4e372cdf Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-0900000000-5ce99348e7f68e7710cb Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-9000000000-f0445ef3c937f78839e0 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9000000000-9ea27d04adb0682d69df Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-9000000000-d1edf9dc1d24d332866f Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9000000000-2296bc0e5c68e047d35a Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 119.036667 predictedDarkChem Lite v0.1.0 [M-H]- 130.69133 predictedDeepCCS 1.0 (2019) [M+H]+ 119.005367 predictedDarkChem Lite v0.1.0 [M+H]+ 133.45277 predictedDeepCCS 1.0 (2019) [M+Na]+ 118.875367 predictedDarkChem Lite v0.1.0 [M+Na]+ 141.94687 predictedDeepCCS 1.0 (2019)
Drug created at December 10, 2020 15:57 / Updated at May 07, 2021 21:09